Imprint cytology of strumal carcinoid of the ovary: A case report with immunocytochemical analysis

Ishida, Mitsuaki; Arimoto, Tomoko; Sandoh, Kaori; Okano, Kimiaki; Ebisu, Yusuke; Itô, Hiroko; Matsumoto, M; Mizokami, Tomomi; Kita, Mihori; Okada, Hidetaka; Tsuta, Koji

doi:10.1002/dc.24042

Cited by 7 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may indicate one of the theories of the development of primary ovarian carcinoid, according to which the carcinoid would develop from the tissues of the teratoma. To confirm the diagnosis immunohistochemical examination is used, which in the presence of neuroendocrine tumor cells shows positive staining for synaptophysin, chromogranin A, peptide YY, CD56 and in the presence of thyroid tissue also for thyroglobulin and thyroid transcription factor-1 (TTF-1) [74][75][76][77][78].…”

Section: Characteristicsmentioning

confidence: 99%

Therapeutic Management of Rare Primary Ovarian Neoplasms: Carcinosarcoma, Leiomyosarcoma, Melanoma and Carcinoid

Kozłowski

Nowak

Kordek

et al. 2021

IJERPH

View full text Add to dashboard Cite

Carcinosarcoma, leiomyosarcoma, melanoma and carcinoid as primary tumors in the ovary are extremely rare. In this paper, the authors reviewed the literature from 2010 to 2021, based on specific criteria, to analyze the treatment of these rare ovarian neoplasms. We also aimed to verify whether modern therapies have been found in recent years. For this article, 80 papers were finally selected. The vast majority of the articles were clinical case reports. Despite single mentions of new potential pharmacological treatments, surgery (radical or fertility-sparing) is definitely the mainstay of treatment. There are currently no treatment guidelines for these tumors. A review of the literature has revealed the use of various adjuvant treatments. We, therefore, believe that a more detailed understanding of the biology of these tumors is necessary in order to find new target points for treatment. We would like to emphasize the importance of creating an international database of rare ovarian tumors which would make it possible to gather data from various oncological centers and enable further research into these neoplasms.

show abstract

Section: Characteristicsmentioning

confidence: 99%

Therapeutic Management of Rare Primary Ovarian Neoplasms: Carcinosarcoma, Leiomyosarcoma, Melanoma and Carcinoid

Kozłowski

Nowak

Kordek

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…Some researchers have found an association between primary ovarian carcinoids and mature cystic teratomas or mucinous tumors, which ultimately complicates preoperative diagnosis and increases the likelihood of missed diagnosis or misdiagnosis [10]. Therefore, a multidisciplinary approach, involving a surgeon, radiologist and pathologist, is required to accurately diagnose strumal carcinoid; immunohistochemical staining is necessary for confirmation and predicting prognosis of the ovarian carcinoid [11].…”

Section: Tumor Pathologymentioning

confidence: 99%

Strumal Carcinoid of the Ovary: A Report of Two Cases

Li¹,

Shah²,

Jia³

et al. 2021

OJOG

View full text Add to dashboard Cite

We describe two cases of strumal carcinoid of ovary, which is an extremely rare ovarian germ cell tumor composed of an intimate mixture of thyroid and carcinoid tissues. The first case involved a 63-year-old woman, who presented with a 1-month history of abdominal distension and unintentional weight loss (5 kg). Abdominal and chest computed tomography revealed right ovarian tumor and bilateral pleural effusion. Her thyroid-stimulating hormone level was slightly lower 0.475 μIU/mL (normal range: 0.55 -4.78 μIU/mL); however, the levels of FT3 and FT4 were normal. Intraoperatively, the right ovary was enlarged (8.0 cm × 7.0 cm), with a smooth surface and intact capsule. Bilateral salpingo-oophorectomy with a total abdominal hysterectomy and an appendectomy was performed. The second case was a 54-year-old woman, in whom pelvic mass was recognized 2 months before. Intraoperatively, the left ovary was dumbbell-shaped (20.0 cm × 9.0 cm × 9.0 cm) and connected to two masses (9.0 cm × 8.0 cm and 8.0 cm × 7.0 cm, respectively). Her thyroid function test was normal (0.70 μIU/mL). Total abdominal hysterectomy, partial omentectomy, and pelvic adhesion lysis were performed. In both patients, intraoperative frozen section suggested strumal carcinoid of the ovary (stage IA). Ovarian strumal carcinoid should be included in a differential diagnosis of adnexal masses. The prognosis is considered good.

show abstract

“…There have only been about 100 cases reported after more than five decades [3]. Characterization of the management of this rarity is mainly accumulated through case report, and treatment strategies have varied greatly, with some researchers arguing for comprehensive staging surgery while others advocated unilateral salpingooophorectomy [2,[5][6][7][8][9]. Postoperative adjuvant therapies, such as chemotherapy and radiotherapy, have also been reported [10,11], but with uncertain benefit.…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics and survival outcomes in patients with ovarian strumal carcinoid

Wang

Sui

et al. 2022

BMC Cancer

View full text Add to dashboard Cite

Background Ovarian strumal carcinoid is an extremely rare ovarian malignant tumor with limited data on clinical characteristics and survival outcomes. Methods A retrospective study of 119 patients was conducted, including 98 cases identified from literature review, and their clinical characteristics were investigated. The overall survival (OS), disease-specific survival (DSS), recurrence-free survival (RFS), and potential prognostic factors of these patients were also evaluated. Results Lesions of 115 cases were confined to the ovarian while four patients presented with extra-ovarian disease upon initial diagnosis. Surgical treatment options performed in this cohort varied, 5.0% received ovarian cystectomy, 36.1% received unilateral salpingo-oophorectomy (USO), 7.6% received bilateral salpingo-oophorectomy (BSO), 42.0% received hysterectomy with BSO, and 8.4% underwent debulking surgery. Moreover, one patient did not undergo any surgery. No postoperative adjuvant therapy was administered in 89.9% patients, while 7.6% and 2.5% received adjuvant radiotherapy and chemotherapy, of which two patients received combined radiation and chemotherapy. At the final follow-up, 89.1% patients showed no evidence of the disease, and 5.0% were alive with the disease. Only seven deaths occurred, with two attributed to the tumor. The 5-year, 10-year, and 20-year OS rates were 96.0%, 85.0%, and 85.0%, respectively, with a 15-year recurrence rate of 4.4%. The 5-year and 20-year DSS rate were 98.5% and 95.9%. Multivariate Cox regression showed age ≥ 55 years was the only risk factor associated with the OS (P = 0.014, OR 7.988; 95% CI 1.519 – 42.004). However, the univariate and multivariate Cox regression showed no potential risk factor for RFS and DSS. Conclusion Patients with ovarian strumal carcinoid have an excellent prognosis irrespective of the surgical option. Conservative surgery especially USO with individualized adjuvant therapy is recommended.

show abstract

Imprint cytology of strumal carcinoid of the ovary: A case report with immunocytochemical analysis

Cited by 7 publications

References 6 publications

Therapeutic Management of Rare Primary Ovarian Neoplasms: Carcinosarcoma, Leiomyosarcoma, Melanoma and Carcinoid

Therapeutic Management of Rare Primary Ovarian Neoplasms: Carcinosarcoma, Leiomyosarcoma, Melanoma and Carcinoid

Strumal Carcinoid of the Ovary: A Report of Two Cases

Clinical characteristics and survival outcomes in patients with ovarian strumal carcinoid

Contact Info

Product

Resources

About